Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system
Carregando...
Citações na Scopus
20
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
MONTEIRO, Lis Marie
LOBENBERG, Raimar
FERREIRA, Elizabeth Igne
CHUNG, Man Chin
BOU-CHACRA, Nadia
Citação
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, v.50, n.1, p.88-92, 2017
Resumo
Dextran-coated poly (n-butyl cyanoacrylate) nanoparticles (PBCA-NPs) were prepared and were evaluated for enhanced delivery of a promising anti-Leishmania drug candidate, hydroxymethylnitrofurazone (NFOH), to phagocytic cells. Currently available chemotherapy for leishmaniasis, such as pentavalent antimonials, presents low safety and efficacy. Furthermore, widespread drug resistance in leishmaniasis is rapidly emerging. To overcome these drawbacks, the use of nanosized delivery systems can reduce systemic drug toxicity and increase the drug concentration in infected macrophages, therefore improving treatment of leishmaniasis. PBCA-NPs containing NFOH (PBCA-NFOH-NPs) were prepared by an anionic emulsion polymerisation method. The z-average and polydispersity index (PDI) were determined by photon correlation spectroscopy, the zeta potential by microelectrophoresis and the entrapment efficiency by HPLC. Cytotoxicity was determined using macrophages from BALB/c mice. Efficacy tests were performed using Leishmania amazonensis promastigotes and amastigotes. The z-average of PBCA-NFOH-NPs was 151.5 +/- 61.97 nm, with a PDI of 0.104 +/- 0.01, a zeta potential of -10.1 +/- 6.49 mV and an entrapment efficiency of 64.47 +/- 0.43%. Efficacy in amastigotes revealed IC50 values of 0.33 mu M and 31.2 mu M for the nanostructured and free NFOH, respectively (95-fold increase). The cytotoxicity study indicated low toxicity of the PBCA-NFOH-NPs to macrophages. The selectivity index was 370.6, which is 49-fold higher than free NFOH (7.6). Such findings indicated that improved efficacy could be due to NP internalisation following site-specific drug delivery and reactivation of immune protective reactions by the NP components. Thus, PBCA-NFOH-NPs have the potential to significantly improve the treatment of leishmaniasis, with reduced systemic side effects.
Palavras-chave
Hydroxymethylnitrofurazone, Poly (n-butyl cyanoacrylate), Leishmaniasis, Drug delivery, Polymeric nanoparticles, Dextran
Referências
- Almouazen E, 2012, INT J PHARMACEUT, V430, P207, DOI 10.1016/j.ijpharm.2012.03.025
- Benedict A., 2015, VIROLOGY, V6, P676
- Bhattacharjee A, 2015, INT J ANTIMICROB AG, V45, P268, DOI 10.1016/j.ijantimicag.2014.10.023
- Choi R, 2010, LANGMUIR, V26, P17520, DOI 10.1021/la1029728
- Davies C, 2010, ANTIMICROB AGENTS CH, V54, P3584, DOI 10.1128/AAC.01451-09
- Duan JH, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0761-4
- Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590
- Freitas-Junior LH, 2012, INT J PARASITOL-DRUG, V2, P11, DOI 10.1016/j.ijpddr.2012.01.003
- Gupta G, 2013, ADV APPL MICROBIOL, V82, P155, DOI 10.1016/B978-0-12-407679-2.00005-3
- Kang YS, 2003, INT IMMUNOL, V15, P177, DOI 10.1093/intimm/dxg019
- Lima SC, 2012, INT J ANTIMICROB AG, V39, P424, DOI 10.1016/j.ijantimicag.2012.01.003
- Lin Y, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/16/165101
- Mahdavian Delavary B, 2011, IMMUNOBIOLOGY, V216, P753, DOI 10.1016/J.IMBIO.2011.01.001
- Monteiro LM, 2015, BRAZ J PHARM SCI, V51, P561, DOI 10.1590/S1984-82502015000300008
- Sarfraz M, 2016, MOL PHARMACEUT, V13, P3270, DOI 10.1021/acs.molpharmaceut.6b00530
- Sham JOH, 2004, INT J PHARM, V269, P457, DOI 10.1016/j.ijpharm.2003.09.041
- Sommerfeld P, 1997, INT J PHARM, V155, P201, DOI 10.1016/S0378-5173(97)00153-1
- Walkey CD, 2012, J AM CHEM SOC, V134, P2139, DOI 10.1021/ja2084338
- Weiss CK, 2007, MACROMOL BIOSCI, V7, P883, DOI 10.1002/mabi.200700046
- Weyermann J, 2004, EUR J PHARM BIOPHARM, V58, P25, DOI 10.1016/j.ejpb.2004.02.011